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Abstract
Background: Among people with type 2 diabetes the relationship between central obesity and cardiovascular mortality has
not been definitely assessed. Moreover, NT-proBNP is negatively associated with central obesity, but no study has examined
their combined effect on survival. We have examined these issues in a well-characterized population-based cohort.
Methods and Findings: Survival data of 2272 diabetic people recruited in 2000 who had no other chronic disease have
been updated to 31 December 2006. NT-proBNP was measured in a subgroup of 1690 patients. Cox proportional hazards
modeling was employed to estimate the independent associations between cardiovascular and all-cause mortality and
waist circumference. Mean age was 67.9 years, 49.3% were men. Both age and NT-proBNP were negatively correlated with
waist circumference (r =20.11, p,0.001 and r =20.07, p = 0.002). Out of 2272 subjects, 520 deaths (221 for CV mortality)
occurred during a median follow-up of 5.4 years. Central obesity was not associated with CV mortality (hazard ratio, HR,
adjusted for age, sex, diabetes duration, 1.14, 95% CI 0.86–1.52). NTproBNP was a negative confounder and age a strong
modifier of this relationship (p for interaction,0.001): age,70 years, fully adjusted model HR = 3.52 (1.17–10.57) and age $
70 years, HR = 0.80 (0.46–1.40). Respective HRs for all-cause mortality were 1.86 (1.03–3.32) and 0.73 (0.51–1.04).
Conclusions: In diabetic people aged 70 years and lower, central obesity was independently associated with increased
cardiovascular mortality, independently of the negative effect of NT-proBNP. In contrast, no effect on 6-years survival was
evident in diabetic people who have yet survived up to 70 years.
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Introduction
Obesity is a strong predictor of diabetes incidence, while the
association between obesity and mortality is more controversial,
most of studies showing an inverse relationship between obesity
and mortality and a modification effect of age [1–8].
Waist circumference positively correlates with abdominal fat
mass, providing a simple and reliable assessment of central obesity,
which is associated with increased mortality risk. However,
prospective data on the predictive role of central obesity on
cardiovascular mortality of diabetic patients are very limited [9].
Central obesity and cardiovascular risk factors, such as glycemic
control, hyperlipidemia, hypertension and microalbuminuria, are
closely interrelated and proper multivariate analyses should be
performed to take into account the independent effect of waist
circumference. Moreover, emerging evidence has pointed out that
natriuretic peptides play a key role in the regulation of body weight
and energy metabolism [10]. N-terminal pro-brain natriuretic
peptide (NT-proBNP), the inactive molecule resulting from
cleavage of BNP pro-hormone, is negatively correlated with
obesity and the strongest predictor of CV mortality in diabetic
patients [11–14]. To our knowledge, however, no prospective
study has provided estimates of CV mortality adjusted for NT-
proBNP, so that the final effect of central obesity on mortality risk
has been probably biased downward. Finally, both in diabetic and
non-diabetic patients age has a modification effect on the
relationship between BMI and mortality, and a similar pattern
could also affect the relationship between central obesity and
mortality [3–7,14].
In this study we have assessed the predictive role of central
obesity on mortality in people with type 2 diabetes recruited as
part of the Casale Monferrato Study, an ongoing population-based
study on the epidemiology of diabetes in Italy, after having
excluded those who had other chronic diseases impairing short-
term survival [15–16]. Aims of the present analyses were: 1) to
assess the role of central obesity on 6-years mortality risk in
diabetic people without other chronic diseases; 2) to define
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whereas age at the baseline examination was a modifier of the
relationship between central obesity and mortality; 3) to examine
the effect of NT-proBNP on this associations.
Methods
The present study was carried out in the second population-
based prevalence survey of the Casale Monferrato Study, which
identified 3249 people with a previous diagnosis of type 2 diabetes
[15–16]. As described in detail elsewhere, participants were
identified from diabetes clinics and other administrative data
sources, obtaining high estimated completeness of ascertainment.
Standardized anthropometric measures were obtained at the
local diabetes clinic. Patients with other chronic disease such as
heart failure, lung and liver diseases and neoplasm, which could
have impaired short-term survival, were excluded from present
analyses, giving a final cohort of 2272 subjects. In a random
subgroup of 1690/2272 (74.3%) patients who had stored plasma
samples, the dosage of NT-proBNP was also performed. With
respect to examined patients, they had similar age (67.7610.4 vs
68.6610.5 years, p = 0.08), duration of diabetes (10.7610.3 vs
10.9610.3 years, p = 0.40), waist circumference (98.0612.1 vs
90.0611.9 cm, p= 0.18), HbA1c (7.061.8 vs 7.261.8), systolic
blood pressure (146.0616.2 vs 145.1617.2, p = 0.30), diastolic
blood pressure (82.568.1 vs 82.868.2 mmHg, p= 0.19), preva-
lence of hypertension (90.6% vs 87.8%, p= 0.06) and CVD
(22.4% vs 21.1%, p= 0.51), as well as plasma levels of lipids, CRP
and uric acid (data not shown).
The study was reviewed and approved by the Ethics Committee
of the S.Giovanni Battista Hospital, Turin. All patients gave
written informed consent to the study, which was carried out in
accordance with the Declaration of Helsinki.
For all patients enrolled, the date of diagnosis was recorded
from clinical charts. Weight and height were measured with
subjects not wearing shoes. Waist circumference was measured at
the midpoint between the lower rib and the iliac crest and central
obesity defined as values .102 cm in men and .88 cm in
women. Hypertension was defined as systolic blood pressure $
140 mm Hg or diastolic blood pressure$ 90 mm Hg or treatment
with anti-hypertensive drugs. Smoking habit was classified as never
smoked, past smoker if the patient had stopped smoking at least 1
month before the visit, and current smoker. All laboratory
determinations were centralized. Venous blood samples for
determination of creatinine, triglycerides, total cholesterol, HDL-
cholesterol (enzymatic colorimetric method after precipitation with
Mn++), apoA1, apoB (turbidimetric method, BM/Hitachi 717,
BBR, Japan) and hemoglobin A1c (HbA1c) (high-performance
liquid chromatography; Daiichi, Menarini, Japan; laboratory
reference range, 3.8–5.5%) were collected after overnight fasting.
LDL-cholesterol was calculated through the Friedewald’s formula.
High-sensitivity (hs)-CRP was measured by immunoturbidimetry
(Roche-Diagnostic, coefficient of variation= 0.5%). AER was
measured by nephelometry (Behring Nephelometer Analyzer,
Behring Institute, Marburg, Germany, coefficient of variation 4%)
on single overnight urine collections and categorised as either
normoalbuminuria (,20 mg/min) or micro/macroalbuminuria ($
20 mg/min). Serum NT-proBNP levels were measured by a two-
site sandwich electrochemiluminescence immunoassay (Elecsys
proBNP II, Roche Diagnostic, Mannheim, Germany), using a
Modular Analytics Evo analyzer with a E170 module (Roche) as
previously described [16]. The intra-assay variation was below
3.0% and total coefficient of variation ranges between 2.2 and
5.8% in low and high ranges of NT-proBNP.
Statistical Analysis
Variables distributed normally are presented as mean and
standard deviation (SD), while variables with skewed distribution
(triglycerides, AER, CRP, NT-proBNP) were analyzed after
logarithmic transformation and results presented as geometric
means and SD. Comparisons were performed using the Student t
test and the x2 test as appropriate. Pearson’s correlation was used
to assess relationships between waist circumference, age and NT-
proBNP.
The relevant time for the analysis was time since diagnosis of
diabetes to death or to 31 December 2006, whichever came first,
with left truncation for the period of time from onset of diabetes to
baseline examination. Information on deaths was obtained from
the demographic registries of the town of residence, hospital
discharge and autopsy records. Only one patient was lost to follow-
up. The underlying causes of death were ascertained and coded
according to the ICD-9 classification. Mortality rates were
calculated by dividing the number of deaths that occurred during
the study period by the whole number of person–years of
observation. Excess of risks of death from cardiovascular diseases
(ICD-9 codes 390–459) and from all causes were expressed as
hazard rate ratios (HRs). Variables-adjusted HRs were calculated
using multivariate Cox proportional hazards models. Given the
time scale, all models were also adjusted for known duration of
diabetes. Models were adjusted for age, sex, diabetes duration
(model 1), systolic blood pressure, cardiovascular diseases (CVD),
HbA1c, LDL-cholesterol, smoking status, logAER, logCRP,
(model 2), and logNT-proBNP (model 3). Subgroup analyses were
conducted according to strata defined by median baseline age (,
70 years vs $70 years). The proportional hazard assumption of
explanatory variables, assessed on the basis of Schoenfeld
residuals, was confirmed. The likelihood ratio test was used to
assess the significance of variables. The p value was two-sided; a p
value,0.05 was considered as being statistically significant. All
analyses were performed with STATA (Release 10.0).
Results
Mean age was 67.9 years, 49.3% were men. People with central
obesity were mainly women and had a worst cardiovascular risk
profile than those without central obesity (Table 1); indeed, they
had higher values of glucose, HbA1c, LDL-cholesterol, apoB,
systolic and diastolic blood pressure, and lower values of HDL-
cholesterol and apoA1. Prevalence of overweight and obesity were
34.3% and 34.2%. The Pearson correlation coefficient was 0.79
(p,0.0001) between BMI and waist circumference, 20.11 (p,
0.001) between age and waist and20.07 (p= 0.002) between waist
circumference and logNT-proBNP, and these results were similar
in men and women.
Out of the total cohort of 2272 subjects, 520 deaths (221 CV
deaths) occurred during a median follow-up of 5.4 years. Risk for
both cardiovascular and all-cause mortality were similar in people
with and without central obesity (Table 2, model 1).
As interaction between age and waist circumference was
statistically significant (p,0.001), we performed stratified analyses
by median age at baseline (,70 vs $70 years). Table 2 shows that
a strong modification effect of age was evident, with a statistically
significant increased risk of both cardiovascular and all-cause
mortality in people aged ,70 yrs: model 1, HR=2.15, 95% CI
1.18–3.92 and HR=1.90, 1.28–2.83, respectively. Risks were
reduced by further adjustment for other cardiovascular risk factors
(model 2).
NT-proBNP was negatively associated with waist circumference
in people aged ,70 years and this effect was evident comparing
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the fully adjusted model 2 with model 3 including also NT-
proBNP (HR=1.75, 0.75–4.08, and HR=3.52, 1.17–10.57,
respectively). In contrast, risk in people aged $70 years was
similar in people with and without central obesity, irrespective of
adjustment for NT-proBNP. Moreover, results were unmodified
after further adjustment for BMI, alcohol consumption and
treatment with drugs for hypertensions and dyslipidemia. Results
were also similar using waist circumference as continuous variable
in models 3, which were separately run by sex: cardiovascular
mortality, age,70 years, men HR=1.07 (1.02–1.12); women HR
1.07 (1.00–1.10); age$70 years, men HR=0.99 (0.95–1.04),
women HR (0.99–0.96–1.03).
Discussion
This study was conducted to investigate the independent
association of central obesity with cardiovascular mortality in a
population-based cohort of people with type 2 diabetes who were
free of other chronic diseases impairing short-term survival. We
found that age was a strong modifier of the relationship between
waist circumference and mortality. Indeed, central obesity was
associated with a statistically significant 3-fold higher cardiovas-
cular mortality in a 6-years follow-up period of people aged 70
years and lower, whereas no effect was evident in those who had
yet survived up to 70 years. This association was independent of
classical and novel risk factors. Finally, NT-proBNP was a negative
confounder of the association between waist circumference and
cardiovascular mortality. The strength of the association between
central obesity and CV mortality in people with type 2 diabetes
was similar to that estimated in non diabetic people and emphasize
the usefulness of this simple measurement in the setting of clinical
practice [17–20].
Several studies have shown that obese persons have lower
circulating natriuretic peptide concentrations than normal weight-
ed persons and a negative linear relationship between BMI, central
obesity and NT-proBNP plasma values has been found both in
diabetic and non-diabetic people [10–14]. This finding has
probably biased downward the strength of the association between
waist circumference and mortality in previous studies. Interesting-
ly, a significant increase in NT-proBNP values following bariatric
surgery has been shown, despite significant improvement in left
ventricular diastolic dysfunction [21]. However, to our knowledge
no previous study has considered the potential effect of NT-
proBNP on the association between central obesity and cardio-
vascular mortality. The natriuretic system and adiposity are closely
linked. Natriuretic peptides have been shown to be important
stimuli for lipolysis in humans, which is similar in potency to
catecholamines, and their effect is independent of both catechol-
amines and insulin pathway [22–23]. Cardiac natriuretic peptides
have emerged as potent metabolic hormones. Experimental
studies have shown their role on adipose tissue metabolism and
on central control of energy balance [24]. In addition to their
Table 1. Characteristics of people with type 2 diabetes of the Casale Monferrato surveys, by central obesity.
Central obesity
Yes (n =1350) No (n=922) P
Age (years) 68.2610.1 67.5610.9 0.15
Men 42.6% 57.5% ,0.0001
Duration (years) 10.867.9 10.768.1 0.89
Glucose (mmol/l) 9.963.1 9.263.0 ,0.0001
HbA1c (%) 7.261.8 6.861.7 ,0.0001
Total colesterol (mmol/l) 5.5661.03 5.3761.03 ,0.0001
LDL-cholesterol (mmol/l) 3.3660.88 3.2360.88 0.0003
HDL-cholesterol (mmol/l) 1.4060.36 1.4760.44 ,0.0001
Triglycerides* (mmol/l) 3.64 (2.54) 2.95 (2.01) ,0.0001
Apo A1 (mg/dl) 155.7636.5 151.6642.6 0.02
Apo B (mg/dl) 105.2626.7 98.2626.4 ,0.0001
Uric acid (mmol/l) 344.986113.01 321.196119.55 ,0.0001
CRP (g/dl)* 3.6 (1.8–7.4) 1.9 (0.8–4.3) ,0.0001
NT-proBNP (pg/ml)* 88.3 (389.8) 87.6 (894.7) 0.91
Systolic blood pressure (mmHg) 147.4616.1 143.41616.7 ,0.0001
Diastolic blood pressure (mmHg) 83.868 81.268.2 ,0.0001
Hypertension 93.2% 85.0% ,0.0001
CVD 22.7% 21.1% 0.37
Current smokers 21.0% 11.1% ,0.001
BMI (Kg/m2) 31.164.8 2.062.9 ,0.0001
Treatment diet 13.6% 18.3% ,0.0001
Oral drugs 77.2% 69.1%
Insulin 9.2% 12.7%
Data are shown as mean 6 SD.
*geometric means (SD).
doi:10.1371/journal.pone.0096076.t001
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impact on lipolysis, NPs are able, via the cGMP/cGK-I pathway,
to modulate and inhibit the secretion of adipokines and cytokines,
such as interleukin-6, interleukin-8 (IL-6, IL-8) and TNF-a, by
adipose tissue, whose increased secretion has been suggested to
play a role in the etiology of the chronic state of low-grade
inflammation and insulin resistance associated with obesity [25].
Various hypotheses have been suggested as possible explana-
tions of the either negative or weak association between obesity
and mortality in the elderly, which might apply to central obesity
in diabetic patients [26]. Overweight might confer improved
survival during recovery from adverse conditions such as infections
or surgical procedures in vulnerable subjects. This protective effect
in the elderly might counterbalance an adverse consequence of
obesity on survival. As an alternative hypothesis, data derived from
observational prospective studies could be affected by survival bias;
indeed, the elderly obese people recruited in these surveys might
represent the subgroup of healthy obese people who survived up to
the baseline examination, thus weakening the association between
obesity and mortality.
Our findings are original and have clinical relevance, providing
evidence that the measurement of waist circumference is useful to
predict risk of death, although limited to diabetic people aged 70
years and lower. Waist circumference cut-off points for the
diagnosis of central obesity are a matter of debate [27–28].
Although different thresholds are used based on sex and ethnicity,
no similar approach has been defined for the elderly. As in
developed countries more than two thirds of people with type 2
diabetes are elderly, our findings have a relevant clinical
implication, suggesting that recommendations for the elderly need
to be individualized.
The present study, relying on well-characterized population-
based cohorts of type 2 diabetic people, extends previous
observations, assessing simultaneously various factors linked to
both central obesity and mortality risk, particularly AER, CRP
and NT-proBNP, the strongest predictor of cardiovascular
mortality. Other strengths of the study include the analysis of
standardized anthropometric measures obtained by trained
physicians rather than data based on self-reports, allowing to
exclude the effect of misclassification; the population-based study
design, allowing to exclude the effect of selection bias; the number
of person-years of observation on which data are based allowing to
provide quite robust data. By excluding patients who had other
chronic diseases at baseline, we minimized the possibility of
reverse causation, that is central obesity might be a consequence
rather than a cause of mortality. Limitation of this study should
also be taken into account. No measurements of either lean body
mass or level of physical and cardiovascular fitness were available.
Moreover, we could not take into account other potential
confounders, such as socioeconomic status, lifestyle and dietary
factors apart from alcohol consumption.
In conclusions, data of the Casale Monferrato Study showed
that in diabetic people aged 70 years and lower, central obesity
was independently associated with a 3-fold increased cardiovas-
cular mortality, independently of the negative effect of NT-
proBNP. In contrast, no effect on 6-years survival was evident in
diabetic people who have yet survived up to 70 years.
Table 2. Association between central obesity and total mortality and CVD mortality in the Casale Monferrato Study.
Deaths
(n)
Mortality rates/1,000
person-years
Model 1 HR*
(95% CI)
Model 2 HR**
(95% CI)
Model 3 HR***
(95% CI)
Cardiovascular mortality
Central obesity
All cohort
no 85 16.8 1.00 1.00 1.00
yes 136 19.8 1.14 (0.86–1.52) 1.03 (0.68–1.56) 1.19 (0.74–1.92)
Age,70 years
no 16 5.8 1.00 1.00 1.00
yes 44 12.7 2.15 (1.18–3.92) 1.75 (0.75–4.08) 3.52 (1.17–10.57)
Age$70 years
no 69 37.4 1.00 1.00 1.00
yes 92 32.7 0.95 (0.68–1.33) 0.84 (0.51–1.36) 0.80 (0.46–1.40)
All-cause mortality
All cohort
no 197 42.8 1.00 1.00 1.00
yes 285 43.4 1.07 (0.88–1.30) 0.97 (0.71–1.29) 0.88 (0.68–1.14)
Age,70 years
No 38 13.8 1.00 1.00 1.00
Yes 96 25.5 1.90 (1.28–2.83) 1.38 (0.83–2.20) 1.86 (1.03–3.32)
Age$70 years
no 159 86.1 1.00 1.00 1.00
yes 189 67.2 0.90 (0.72–1.13) 0.84 (0.51–1.36) 0.73 (0.51–1.04)
*adjusted for age, sex, diabetes duration.
**adjusted also for systolic blood pressure, HbA1c, LDL-cholesterol, smoking, CVD, logCRP, logAER.
***adjusted also for logNT-proBNP.
doi:10.1371/journal.pone.0096076.t002
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